A B S T R A C T In a young woman with ulcerative colitis, hypoimmunoglobulinemia, and humoral immunodeficiency, lymphocyte counts vary between 600 and 1,000 per mm3 with 0.5-1.5% bone marrowderived (B) cells and 98-99% thymus-derived (T) cells. Anti-lymphocyte antibodies were detected by immunofluorescence and by microlymphocytotoxicity with increased reactivity at +4°C. They belonged to the IgM class and were polyclonal. Studies performed with various normal lymphocyte subpopulations, several lymphoblastoid cell lines and lymphocytes from immunodeficiency patients showed that these antibodies reacted with B cells. The corresponding antigen(s) is distinct from membrane-bound immunoglobulins, is not an alloantigen, and is probably unrelated to the la-like molecules. Pokeweed mitogen stimulated B cells appear to lose this antigen. Cells from various lymphoproliferative disorders were tested. T-derived and "non T-non-B" leukemic cells did not react with the antibody. Malignant cells from B-derived lymphomas and prolymphocytic leukemias were reactive. The incidence of positivity of the leukemic cells among patients with common B chronic lymphocytic leukemia was surprisingly low (one-third of the patients).
INTRODUCTION
Most primary immunodeficiency (ID)1 syndromes appear to result from an arrest in the differentiation capabilities of immunologically competent cells at various stages (1) . However other mechanisms such as specific killing of normally maturing lymphocytes by lymphocytotoxic autoantibodies could be incriminated in the pathogenesis of some ID. Lymphocytotoxins have been recently reported in a variety of human diseases, including systemic lupus erythematosus and inflammatory bowel diseases (2, 3) . The data on the occurrence of such anti-lymphocyte antibodies in patients with ID are very scarce (4, 5) . In the hitherto reported cases neither a definite anti-B (bone marrow-derived) or anti-T (thymus-derived) specificity nor a clear relationship with immunodepression have been established. IAbbreviations Reactivity with cells from lymphoproliferative diseases. As shown in Table III , leukemic T-derived cells (9) and acute lymphoblastic leukemia cells were not reactive with D.S. antibody whereas proliferating B-derived cells from patients with lymphomas or y-chain disease gave positive results. In contrast to these results and to the fact that most B lymphocytes from all normal individuals react with D.S. antibody, the incidence of B-derived chronic lymphocytic leukemia (CLL) with reactive leukemic cells was surprisingly low. In those negative B CLL cases which were further studied, the absence of the antigen(s) combining with D.S. antibody was confirmed by the unability of these leukemic cells at +4°C. The anti-B-cell specificity of these autoantibodies was established by double labeling experiments and by the study of normal lymphocyte subpopulations, lymphoblastoid cell lines, and cells from patients with ID or with lympho-proliferative diseases. However a small subset of circulating B cells (1% of PBL) appears to lack the corresponding antigen(s) which conversely may be present on a small subset (1% of PBL) of cells expressing T markers.
The precise nature of the B-cell antigen(s) that react with D.S. antibodies remains unknown. These antigen(s) are clearly distinct from SIg since they were shown to cap independently and since D.S. antibodies react with Raji cells (which lack SIg) and fail to react with SIg-bearing PWM-stimulated lymphocytes. In view of their presence on the B cells from all normal individuals so far tested, the antigenic determinant(s) revealed by D.S. antibodies appear to be distinct from the group of B-cell alloantigens which have close similarity to the Ia antigens of the mouse (11) . Moreover they appear to be distinct from the common determinants of these Ia-like molecules revealed by various hetero-antisera (12) (13) (14) since D.S. antibodies react with fibroblasts, do not react with cells from patients with "non-B-non-T" acute lymphoblastic leukemias, and fail to inhibit mixed lymphocyte reactions (in experiments kindly performed by Dr. Fradelizi).
The surprising lack of reactivity of D.S. antibodies with the proliferating cells from two-thirds of patients with common B CLL can probably not be explained on the basis of the arising of these leukemic clones from a negative B-cell subset since such a subset accounts for less than 5% of normal B PBL. Whether this negative finding is related to the neoplastic nature of the CLL cells or to the various levels in the differentiation pathway of the B-cell line where proliferating clones from individual CLL patients appear to be blocked (6) (4) . In another boy with recurrent infections and deficiency of both cellular and humoral immunity, a high titer IgM antibody to IgG was found and was thought to be responsible for a non-HLA associated lymphocytotoxicity which was blocked by IgG (5) . In patient D.S., it may be assumed that the antibody to B lymphocytes is an autoantibody and that it played a crucial role in the pathogenesis of hypoimmunoglobulinemia, since the withdrawal of this antibody by plasmapheresis was followed by a dramatic and transitory increase in the number of circulating B lymphocytes. Since those B cells which escape the noxiousness ofthe autoantibodies are presumably able to differentiate normally, it is not surprisirng that in patient D.S. the very low figures for circulating B cells contrasted with a fair but not extremely profound hypoimmunoglobulinemia, a relatively moderate impairment of humoral immunity (with normal cellular immunity), the presence of germinal centers in the mesenteric lymph nodes, and grossly normal figures for plasma cells in the intestinal tract. Autoantibodies to B lymphocytes should be systematically searched in patients with ID when such discrepancies are observed.
